EIP Pharma, a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, agreed to merge with Diffusion Pharmaceuticals, a biotechnology company. Financial terms were not disclosed. “With this proposed merger, we are creating a leading company focused on developing treatments for neurodegenerative diseases, beginning first with neflamapimod for the treatment of dementia with Lewy bodies, the second most common type of dementia after Alzheimer’s disease, and for which there are currently no approved treatments,” John Alam, EIP Pharma CEO.